Episode
E138: Dapirolizumab for SLE (PHOENYCS-GO)
- Published
- Jul 24, 2026
- Duration seconds
- 1329
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e138-dapirolizumab-for-sle-phoenycs-go/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e138-dapirolizumab-for-sle-phoenycs-go.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
A new therapy for SLE! This one is a CD40-CD40L blocker, which has some nice new-things to inhibit. The study itself was a qualified success and the podcast got a bit more rant-y than it should have been, but hopefully you get a kick out of it. Paper: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00691-4/fulltext